# A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

> **NCT02129075** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 60 (actual)

## Conditions studied

- Cutaneous Melanoma
- Melanoma
- Melanoma of Unknown Primary
- Mucosal Melanoma
- Ocular Melanoma
- Stage IIB Cutaneous Melanoma AJCC v6 and v7
- Stage IIC Cutaneous Melanoma AJCC v6 and v7
- Stage III Cutaneous Melanoma AJCC v7
- Stage IIIA Cutaneous Melanoma AJCC v7
- Stage IIIB Cutaneous Melanoma AJCC v7
- Stage IIIC Cutaneous Melanoma AJCC v7
- Stage IV Cutaneous Melanoma AJCC v6 and v7

## Interventions

- **BIOLOGICAL:** DEC-205/NY-ESO-1 Fusion Protein CDX-1401
- **DRUG:** Poly ICLC
- **BIOLOGICAL:** Recombinant Flt3 Ligand

## Key facts

- **NCT ID:** NCT02129075
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-09
- **Primary completion:** 2016-03-28
- **Final completion:** 2018-05-18
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02129075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02129075, "A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02129075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*